Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.

QR kód

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.

There is evidence that it is safe and effective for patients with inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original infliximab drug to a biosimilar, but little is known about outcomes of reverse switches and/or multiple switches. We aimed to evaluate the effects o...

Teljes leírás

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Iliás Ákos Szántó Kata Gönczi Lóránt Kürti Zsuzsanna Golovics Petra Anna Farkas Klaudia Szepes Zoltán Szalay Balázs Vincze Áron Molnár Tamás Lakatos Péter László
Dokumentumtípus:	Cikk
Megjelent:	2019
Sorozat:	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 17 No. 12
doi:	10.1016/j.cgh.2018.12.036
mtmt:	30388151
Online Access:	http://publicatio.bibl.u-szeged.hu/15467

Hasonló tételek

Switching from infliximab to biosimilar in inflammatory bowel disease
Szerző: Milassin Ágnes, et al.
Megjelent: (2019)

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study
Szerző: Lontai Livia, et al.
Megjelent: (2022)

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /
Szerző: Sarlós Patrícia, et al.
Megjelent: (2023)

Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients
Szerző: Bacsur Péter, et al.
Megjelent: (2022)

Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease
Szerző: Ellul Pierre, et al.
Megjelent: (2023)

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases results from Central European nationwide cohort /
Szerző: Bálint Anita, et al.
Megjelent: (2017)

A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Szerző: Farkas Klaudia, et al.
Megjelent: (2018)

Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases a prospective; multicentre; nationwide cohort /
Szerző: Gecse Krisztina Barbara, et al.
Megjelent: (2016)

Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy
Szerző: Bálint Anita, et al.
Megjelent: (2015)

Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease An ECCO CONFER Case Series /
Szerző: Phillips Frank, et al.
Megjelent: (2022)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
Szerző: Gönczi Lóránt, et al.
Megjelent: (2017)

Spotlight on Transition in Patients With Inflammatory Bowel Disease A Systematic Review /
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Lupus-like reactions in patients with inflammatory bowel disease
Szerző: Pigniczki Daniella, et al.
Megjelent: (2019)

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease long-term extension data from a Phase 3 study /
Szerző: Schmidt Christoph, et al.
Megjelent: (2016)

Improving disease management of patients with inflammatory bowel disease the potential role of self-concordant health goals /
Szerző: Horvát Barbara, et al.
Megjelent: (2023)

Inflammatory Bowel Disease-Mimicking Colitis Associated With Nintedanib-Based Therapy in a Lung Cancer Patient
Szerző: Sejben Anita, et al.
Megjelent: (2023)

How do you like the pen? Patients' opinion about switching adalimumab from prefilled syringe to pen in inflammatory bowel disease
Szerző: Szántó Kata, et al.
Megjelent: (2018)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
Szerző: Bacsur Péter, et al.
Megjelent: (2023)

Importance of Diet in Inflammatory Bowel Disease – Data from the Patients’ View
Szerző: Molnár Tamás, et al.
Megjelent: (2014)

Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease An ECCO CONFER Multicentre Case Series /
Szerző: Festa Stefano, et al.
Megjelent: (2022)

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Szerző: Gordon Hannah, et al.
Megjelent: (2023)

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
Szerző: Mandel Michael D., et al.
Megjelent: (2014)

Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease a meta-analysis /
Szerző: Sarlós Patrícia, et al.
Megjelent: (2018)

New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents Cyclosporine Plus Vedolizumab /
Szerző: Szántó Kata Judit, et al.
Megjelent: (2018)

Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab
Szerző: Szemes Kata, et al.
Megjelent: (2024)

Tuberculin skin test and Quantiferon in BCG vaccinated; immunosuppressed patients with moderate-to-severe inflammatory bowel disease
Szerző: Kürti Zsuzsanna, et al.
Megjelent: (2015)

Iron Deficiency Anemia in Inflammatory Bowel Disease What Do We Know? /
Szerző: Resál Tamás, et al.
Megjelent: (2021)

Inflammatory Bowel Disease and Physical activity a study on the impact of diagnosis on the level of exercise amongst patients with IBD /
Szerző: Gatt K., et al.
Megjelent: (2019)

Surgery Due to Inflammatory Bowel Disease During Pregnancy Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study) /
Szerző: Chaparro María, et al.
Megjelent: (2022)

Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center
Szerző: Szántó Kata, et al.
Megjelent: (2018)

Adverse events associated with management of inflammatory bowel diseases infections and side effects /
Szerző: Bálint Anita
Megjelent: (2015)

The Role of Gut Permeability and Serine-Proteases in the Pathomechanism of Irritable Bowel Syndrome and Inflammatory Bowel Diseases
Szerző: Gecse Krisztina
Megjelent: (2012)

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
Szerző: Rahier Jean-Francois, et al.
Megjelent: (2011)

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
Szerző: Sánta Anett, et al.
Megjelent: (2023)

Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients A cross-sectional study /
Szerző: Szántó Kata Judit, et al.
Megjelent: (2021)

Serological Status of Inflammatory Bowel Disease Patients Before Starting Biological Therapy - Data From a Tertiary Centre of the Best Vaccined Country.
Szerző: Szántó Kata, et al.
Megjelent: (2020)

Elevated Expression of AXL May Contribute to the Epithelial-to- Mesenchymal Transition in Inflammatory Bowel Disease Patients
Szerző: Boros Éva, et al.
Megjelent: (2018)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases A European retrospective observational study /
Szerző: Goessens Laurent, et al.
Megjelent: (2021)

Barriers in inflammatory bowel disease care in Central and Eastern Europe a region-specific analysis /
Szerző: Prokopič Michal, et al.
Megjelent: (2023)